Charles River Laboratories International Inc

The top contract research organizations have opportunities to gain share in a rapidly growing industry.

The means and motives for deals are in place, but macroeconomic fears will likely keep the M&A market in waiting.

The contract research organization industry's recovery is finally making its way into earnings and valuations.

Despite a big runup in 2012, shares in these firms still look attractively priced.

The current stock price assigns almost no value to this top-tier CRO's preclinical services segment.

Contract research organizations remain on sale as industry rebound gains steam.

Market uncertainty has uncovered opportunity in this high-growth sector.

Hoping to buy on the dip? These stocks are a good place to look.

Looking to buy on the dip? These stocks are a good place to look.

Despite bookings improvement, firms continue to trade below fair value.

Near-term demand remains choppy, but bookings growth shows CRO model promise.

Mergers and acquisitions replace reform as a key health-care topic.

Slow growth persists among CROs, but we see a rebound on the horizon.

The near-term environment remains tough, but we're bullish on the CROs' long-term prospects.

Despite near-term challenges, we think contract research providers are set for long-run gains.

Stock in this lab research-services firm has been beaten down too far.

Market challenges the defensive nature of health care.

Despite changing political winds, we're still bullish on these five firms.

CROs can offer safety in an explosive industry.

Baron is bullish on stocks, but continues to avoid tech stocks.